Moviegoers are showing up again. Investors, not so much. Shares of AMC Entertainment Holdings Inc (NYSE:AMC) are down more than 50% year to date, trading around $1.75 — just off 52-week lows — even as the company posts its strongest pre-Christmas weekend since 2021. Attendance surged on the back of “Avatar: Fire and Ash,” with more than four million customers visiting AMC and ODEON locations globally.Track AMC stock here.The disconnect hasn't gone unnoticed.Read Also: AMC Entertainment Stock Hits A New All- ...

U.S. stocks settled higher on Friday, with the Nasdaq Composite gaining around 300 points during the session as investors continued to show optimism towards the AI theme and positioned into December’s “triple witching” session.The Dow Jones closed higher by around 183 points to 48,134.89 on Friday. The S&P 500 rose 0.88% to 6,834.50, while the Nasdaq Composite jumped 1.31% to 23,307.62 during Friday's session.Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all an ...

BitMine Immersion Technologies Inc (NYSE:BMNR) added 98,852 Ethereum (CRYPTO: ETH) in the past week as the stock trades around $31 on Monday, just $2 above a critical support level.BMNR Holdings Hit 4 Million ETHBitmine now owns 3.37% of ETH’s circulating supply, two-thirds of the way to Chairman Thomas Lee’s “Alchemy of 5%” target.The company crossed 4.066 million ETH after just 5.5 months of aggressive accumulation, cementing its position as the world’s largest Ethereum treasury. Total assets including $1 ...

CRISPR Therapeutics AG (NASDAQ:CRSP) on Monday provided updates on zugocaptagene geleucel (zugo-cel, formerly CTX112), its investigational allogeneic CAR T targeting CD19, in development for autoimmune disease and hematologic malignancies.Autoimmune DiseaseZugo-cel, targeting CD19, is in an ongoing Phase 1 basket trial in autoimmune rheumatologic diseases.Preliminary clinical data from the Phase 1 study have been encouraging, and zugo-cel has been well-tolerated to date.Also Read: CRISPR Therapeutics’ Inves ...

Conagra Brands Inc (NYSE:CAG) reported mixed results for the second quarter on Friday.The company reported quarterly earnings of 45 cents per share which beat the analyst consensus estimate of 44 cents per share. The company reported quarterly sales of $2.979 billion which missed the analyst consensus estimate of $2.986 billion.Sean Connolly, president and chief executive officer of Conagra Brands, said, “While we continued to navigate a challenging consumer environment in the second quarter, I am pleased w ...

Conagra Brands Inc (NYSE:CAG) reported mixed results for the second quarter on Friday.The company reported quarterly earnings of 45 cents per share which beat the analyst consensus estimate of 44 cents per share. The company reported quarterly sales of $2.979 billion which missed the analyst consensus estimate of $2.986 billion.Sean Connolly, president and chief executive officer of Conagra Brands, said, “While we continued to navigate a challenging consumer environment in the second quarter, I am pleased w ...

核心财务表现 - 公司2025财年第二季度总营收同比增长18%至15.57亿美元 [1] - 季度调整后稀释每股收益为1.26美元，高于去年同期的1.14美元 [1] - 季度GAAP稀释每股收益为1.10美元，略低于去年同期的1.14美元 [1] - 调整后每股收益超出市场预期0.03美元，但营收低于预期1000万美元 [1] 管理层评论与展望 - 管理层认为在关键战略重点上取得重大进展，提供了业内最全面的人力资本管理解决方案套件 [2] - 将战略进展和人工智能驱动的生产力归因于效率提升和客户价值增加 [2] - 公司将2026财年调整后每股收益增长展望上调至10%-11%，指引区间调整为每股5.48美元至5.53美元 [2] 市场反应与股价 - 财报发布后，公司股价在周一上涨2.1%，至114.66美元 [2] 分析师评级与目标价调整 - 摩根士丹利分析师维持“均配”评级，将目标价从133美元下调至123美元 [4] - 摩根大通分析师维持“低配”评级，将目标价从140美元下调至125美元 [4] - 花旗集团分析师维持“中性”评级，将目标价从139美元下调至120美元 [4]

核心财务表现 - 公司2025财年第二季度总营收同比增长18% 达到15.57亿美元 [1] - 季度调整后稀释每股收益为1.26美元 高于去年同期的1.14美元 [1] - 季度GAAP稀释每股收益为1.10美元 略低于去年同期的1.14美元 [1] - 调整后每股收益超出市场预期0.03美元 但营收低于预期1000万美元 [1] 管理层评论与展望 - 管理层将业绩归因于关键战略优先事项的显著进展以及人工智能驱动的生产力提升 [2] - 公司上调了2026财年调整后每股收益增长指引至10%-11% [2] - 2026财年调整后每股收益指引范围更新为5.48美元至5.53美元 [2] 市场反应与分析师观点 - 财报发布后 公司股价在周一上涨2.1% 至114.66美元 [2] - 摩根士丹利分析师维持“均配”评级 但将目标价从133美元下调至123美元 [4] - 摩根大通分析师维持“低配”评级 并将目标价从140美元下调至125美元 [4] - 花旗集团分析师维持“中性”评级 并将目标价从139美元下调至120美元 [4]

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.The Dow traded up 0.39% to 48,322.06 while the NASDAQ jumped 0.46% to 23,417.50. The S&P 500 also rose, gaining, 0.46% to 6,866.26.Check This Out: GE Vernova To Rally Around 26%? Here Are 10 Top Analyst Forecasts For MondayLeading and Lagging SectorsMaterials shares rose by 1.3% on Monday.In trading on Monday, utilities stocks fell by 0.2%.Top HeadlineUniFirst Corp (NYSE:UNF) received an acquisi ...

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 150 points on Monday.The Dow traded up 0.39% to 48,322.06 while the NASDAQ jumped 0.46% to 23,417.50. The S&P 500 also rose, gaining, 0.46% to 6,866.26.Check This Out: GE Vernova To Rally Around 26%? Here Are 10 Top Analyst Forecasts For MondayLeading and Lagging SectorsMaterials shares rose by 1.3% on Monday.In trading on Monday, utilities stocks fell by 0.2%.Top HeadlineUniFirst Corp (NYSE:UNF) received an acquisi ...